Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25789867 | 0.77 | NNMT (0.45) | NNMTHTR2AHTR2CHTR2B | |
| SCHEMBL25425626 | 0.76 | NNMT (0.47) | NNMTHTR2AHTR2CHTR2B | |
| SCHEMBL25425630 | 0.76 | NNMT (0.47) | NNMTHTR2AHTR2CHTR2B | |
| SCHEMBL13485118 | 0.73 | NNMT (0.39) | NNMTHTR2A | |
| SCHEMBL13507512 | 0.73 | NNMT (0.42) | NNMT | |
| SCHEMBL21323893 | 0.70 | HTR2A (0.43) | NNMTHTR2AHTR2CHTR2B | |
| SCHEMBL16019530 | 0.68 | UHRF1 (0.41) | HTR2AHTR2CHTR2B | |
| SCHEMBL21104269 | 0.68 | CCNB2 (0.36) | HTR2AHTR2CHTR2B | |
| SCHEMBL21100678 | 0.67 | KDM4E (0.36) | HTR2AHTR2CHTR2B | |
| SCHEMBL10199838 | 0.67 | HTR2A (0.37) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393623-A1 | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2021-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393623-A1 | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors | PTPN1, PTPN5, PTPN2 | NNMT 2138/4885HTR2A 4145/4885HTR2C 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.